IP Library › Granted Patent US 12,098,130
Granted Patent B2
US 12,098,130 · App. 18/327,986 · Granted Sep 24, 2024

1,4-substituted piperidine derivatives

Inventors: Nadine C. Becknell (Coatesville, PA); Reddeppa Reddy Dandu (Downingtown, PA); Bruce D. Dorsey (Ambler, PA); Dimitar B. Gotchev (Hatboro, PA); Robert L. Hudkins (Chester Springs, PA); Linda Weinberg (King of Prussia, PA); Craig A. Zificsak (Downingtown, PA); Allison Zulli (Wayne, PA)
Assignee: 89BIO LTD
C07D211/44C07D211/54C07D211/58C07D401/04C07D401/12C07D401/14C07D405/06C07D405/12C07D405/14C07D409/12C07D409/14C07D413/14C07D417/12C07D417/14C07D471/02C07D471/04C07D471/08C07D491/048C07D495/02C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,130
App. No.
18/327,986
Granted
Sep 24, 2024
Kind
B2
Abstract

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

Claims (19)

1. A method of treating a subject who is suffering from a condition, disease, or disorder, wherein said condition, disease, or disorder is obesity, an eating disorder, cardiovascular disease, a gastrointestinal disorder, a dermatological disorder, non-alcoholic hepatic steatosis (NASH), Type 2 diabetes, a viral disorder wherein FASN inhibition correlates inhibition of viral replication, breast cancer, ovarian cancer, prostate cancer, colon cancer, lung cancer, bladder cancer, stomach cancer, kidney cancer, or cancer metastasis, said method comprising administering to the subject a therapeutically effective amount of a compound according to Formula:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the condition, disease, or disorder is obesity.

3. The method of claim 1 , wherein the condition, disease, or disorder is an eating disorder.

4. The method of claim 1 , wherein the condition, disease, or disorder is cardiovascular disease.

5. The method of claim 1 , wherein the condition, disease, or disorder is a gastrointestinal disorder.

6. The method of claim 1 , wherein the condition, disease, or disorder is a dermatological disorder.

7. The method of claim 1 , wherein the condition, disease, or disorder is non-alcoholic hepatic steatosis (NASH).

8. The method of claim 1 , wherein the condition, disease, or disorder is Type 2 diabetes.

9. The method of claim 1 , wherein the condition, disease, or disorder is a viral disorder wherein FASN inhibition correlates inhibition of viral replication.

10. The method of claim 1 , wherein the condition, disease, or disorder is breast cancer.

11. The method of claim 1 , wherein the condition, disease, or disorder is ovarian cancer.

12. The method of claim 1 , wherein the condition, disease, or disorder is prostate cancer.

13. The method of claim 1 , wherein the condition, disease, or disorder is colon cancer.

14. The method of claim 1 , wherein the condition, disease, or disorder is lung cancer.

15. The method of claim 1 , wherein the condition, disease, or disorder is bladder cancer.

16. The method of claim 1 , wherein the condition, disease, or disorder is stomach cancer.

17. The method of claim 1 , wherein the condition, disease, or disorder is kidney cancer.

18. The method of claim 1 , wherein the condition, disease, or disorder is cancer metastasis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: 89BIO LTD.
To: CEPHALON LLC
Reel/Frame 072730/0677 →
Continuity (6)
Continuation 17090375 · Nov 5, 2020
Continuation 16257591 · Jan 25, 2019
Continuation 15903150 · Feb 23, 2018
Continuation 15185710 · Jun 17, 2016
Provisional Application 62181384 · Jun 18, 2015
Related Publication 20230391723A1 · Dec 7, 2023